The Skin Doctors Conducts the Seminar to Protect Coronary Artery Disease
Food and Healthcare Press Releases Friday November 11, 2011 14:52The Skin Doctors conducts the seminar for health lovers in a topic “The Coronary Artery Disease prevention with Anti-Aging health care”. The seminar session is scheduled to be held at “The Skin Doctors Central Chidlom 8th Floor” on Saturday, November 19, 2011 from 1.00-4.00 p.m., and will be presented and advised by Anti-Aging professional from our institute; Dr. Luckhana Thawaroj together with a celebrity; Khun Duangjai Hathaikarn, who is going to join the talk.
In the seminar all participants can also join many activities such as blood sugar measurement, blood pressure measurement, complete blood count measurement to scan mental and toxin, cardiovascular system and toxin accumulation in liver.
Special offer for first 20 participants, get free aging cell analysis with LBA technology valued 5,500 Baht. Free reservation. Please contact Outside Marketing Team Tel: 02-696-1286-7 or 085-4876927 (Limited seat available).
Latest Press Release
Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, today announces that the Beijing Intellectual Property Court has confirmed judgment against Wuxi Hisky Medical,...
By Susan Bowerman, M.S., RD, CSSD, CSOWM, FAN, Senior Director, Worldwide Nutrition Education and Training Make your daily staples as healthy as you can. Small changes in the foods you eat every day can add up to big rewards. The holidays are over, and...
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently performed the first procedure in the U.S. using the new HELIOSTAR Multi-electrode Radiofrequency (RF) Balloon Ablation Catheter as part of the STELLAR study. The study...
Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO(R) (avelumab) in combination with INLYTA(R) (axitinib)*...
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"),...